Reuters logo
BRIEF-Alnylam Pharma says discontinues revusiran development
October 5, 2016 / 8:56 PM / a year ago

BRIEF-Alnylam Pharma says discontinues revusiran development

Oct 5 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam pharmaceuticals discontinues revusiran development

* Decision to discontinue development of revusiran does not affect patisiran

* Decision to discontinue development of revusiran does not affect any other investigational rnai therapeutic program in development

* Upon recommendation of endeavour phase 3 study dmc to suspend dosing, decided to discontinue development of revusiran

* Alnylam pharmaceuticals inc says decision does not impact patisiran or any other rnai therapeutic program in development

* Subsequently reviewed unblinded endeavour data which revealed an imbalance of mortality in revusiran arm as compared to placebo

* Reaffirms its “alnylam 2020” guidance and remains committed to advancement of investigational rnai therapeutics Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below